{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041148","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.173858+00:00","generated_at":"2026-06-04T05:10:25.121045+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Eloxx reprices CEO Sumit Aggarwal's options to $0.90 from $37.47 per share","bullets":["Option repricing approved by Board on March 25, 2024 for CEO Sumit Aggarwal.","Exercise price reduced to $0.90 per share (closing price on March 25, 2024).","Affects 196,880 shares previously exercisable at weighted average $37.47.","All outstanding eligible options under 2018 Equity Incentive Plan included."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041148","json":"https://secwatch.observer/filing/0001104659-24-041148.json","markdown":"https://secwatch.observer/filing/0001104659-24-041148.md","text":"https://secwatch.observer/filing/0001104659-24-041148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924041148/0001104659-24-041148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924041148/tm248887d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:10:25.121045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}